Select language:

COVID-19 drug registered in Russia

 / Главная / Russkiy Mir Foundation / News / COVID-19 drug registered in Russia

COVID-19 drug registered in Russia


15.11.2021

Photo credit: Myriams-Fotos / pixabay.com

The COVID-19 medicine has successfully passed registration in Russia, RIA Novosti reports. The drug entitled "Areplivir" is licenced for the civilian circulation for the next five years.

The international name of the drug is Favipiravir. It was created and released by specialists from the Biochemist plant in Saransk. The plant belongs to the Promomed company.

At the beginning of 2021, the plant increased the production of the drug tenfold. Up to a million packages are produced monthly.

Areplivir is included in the guidelines of the Ministry of Health for the treatment of coronavirus. It is also on the list of vital and essential medicines. Its recommended price is 5060 rubles.

Previously, Japanese scientists used Favipiravir for treatment of diseases caused by RNA viruses. When the coronavirus epidemic began, it was used by Chinese and Japanese doctors. The patent, for Favipiravir ended in 2019. Many pharmaceutical companies started work to create a copy of this drug.

Russkiy Mir

News by subject

Publications

Marco Maggi: ”Russian to the Bone" 20.01.2024
Italian entrepreneur Marco Maggi's book, "Russian to the Bone," is now accessible for purchase in Italy and is scheduled for release in Russia in the upcoming months. In the book, Marco recounts his personal odyssey, narrating each stage of his life as a foreigner in Russia—starting from the initial fascination to the process of cultural assimilation, venturing into business, fostering authentic friendships, and ultimately, reaching a deep sense of identifying as a Russian at his very core.